Ionis Pharmaceuticals

ISIN US4622221004

WKN A2ACMZ

Market cap (in EUR)

11,351 m

Country

United States

Sector

Healthcare

Dividend yield

0.00%

Overview

Quote

Description

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Show more Show less

Healthcare Biopharmaceuticals Other Biopharmaceuticals United States

Chart

Financials

Key metrics

Market capitalisation, EUR	11,351 m
EPS, EUR	-1.55
P/B ratio	21.3
P/E ratio	-
Dividend yield	0.00%

Income statement (2024)

Revenue, EUR	652 m
Net income, EUR	-420 m
Profit margin	-64.37%

What ETF is Ionis Pharmaceuticals in?

There are 5 ETFs which contain Ionis Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Ionis Pharmaceuticals is the L&G Pharma Breakthrough UCITS ETF.

ETF	Weight	Investment focus	Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	1.02%	Equity United States Health Care Biotech	44
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing	0.01%	Equity World Social/Environmental	483
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing	0.02%	Equity North America Social/Environmental	27
L&G Pharma Breakthrough UCITS ETF	2.96%	Equity World Health Care Innovation	16
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist)	0.18%	Equity United States Small Cap	176

Performance

Returns overview

YTD	+106.11%
1 month	+8.00%
3 months	+34.24%
6 months	+128.30%
1 year	+102.07%
3 years	+90.29%
5 years	+67.29%
Since inception (MAX)	+11.64%
2024	-25.48%
2023	+30.77%
2022	+29.46%
2021	-42.04%

Monthly returns in a heat map

Risk

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF returns include dividend payments (if applicable).